Dayprox® is a preparation of oxaprozin, a nonsteroidal anti-inflammatory agent (NSAIDs). It is an inhibitor of prostaglandin synthesis, which exhibits anti-inflammatory, analgesic and antipyretic activity.

Dayprox® is indicated for the treatment of rheumatoid arthritis, osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, tendonitis, bursitis and acute gout. It is also indicated for the relief of mild to moderate pain.

Adult: 1200 mg per day taken in single dose or two divided doses. The total daily dose of Dayprox® should not exceed 1800 mg. (26 mg/kg, whichever is lower) in oral adminisrtration.
Children:
For juvenile rheumatoid arthritis:
The usual dose for children over 6-16 years is recommended, the dose given orally once per day base on the body weight as follows:

Oxaprozin is contraindicated in acute peptic ulcer or if there is any hypersensitivity to Oxaprozin. It should not be given to patients in whom aspirin or other nonsteroidal anti-inflammatory/analgesic drugs induce asthma, rhinitis or urticaria.

Teratogenic effects of Oxaprozin showed – Pregnancy Category C in animal studies. There are no adequate or well-controlled studies in pregnant women or lactating mother. Oxaprozin should be used during Pregnancy only if the potential benefits justify the potential risks to the fetus and use in nursing mother should be avoided.

Dayprox® should be given with precautions if there is any gastrointestinal diseases, bronchial asthma, allergic diseases, impaired renal function etc.

The more frequent reactions are nausea, vomiting, abdominal discomfort and epigastric distress, skin rashes, urticaria, tinnitus, edema, headache, insomnia, cognitive dysfunction, anemia etc. The more serious reactions like gastrointestinal bleeding, peptic ulceration, haemorrhage, perforation, colitis etc. may occur occasionally.

Dayprox® and other non-steroidal anti-inflammatory drugs can reduce the anti-hypertensive effect of propranolol and other beta-blockers. The natriuretic effects of frusemide have been reported to be inhibited by some drugs of this class. Concurrent administration of methotrexate may enhance its toxicity due to reduce tubular secretion. Animal studies indicate that the prompt administration of activated charcoal in adequate amounts would tend to reduce markedly the absorption of the drug.

Significant over dosage of the drug may be characterized by drowsiness, heartburn, indigestion, and nausea or vomiting. It is not known what doses of the drug (if any) would be life threatening.

Store in a cool, dry place and protect from light. Keep out of reach of children.

Dayprox® tablet:  Box containing 3 strips of 10 tablets each. Each film coated tablet contains Oxaprozin USP 600 mg.



Manufactured by:
ESKAYEF BANGLADESH LTD
DHAKA, BANGLADESH
® REGD.TRADEMARK